Skip Navigation

Jacqueline S. Garcia, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Physician
  • Assistant Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Leukemias
  • MDS
  • Myeloproliferative neoplasms

Diseases Treated

Contact Information

  • Appointments617-632-1906
  • Office Phone Number617-632-1906
  • Fax617-582-9806

Board Certification:

  • Hematology, 2014
  • Internal Medicine, 2011
  • Medical Oncology, 2015

Fellowship:

  • Stanford University, Hematology/Oncology

Residency:

  • University of Chicago Hospitals, Illinois, Internal Medicine

Medical School:

  • University of Illinois at Chicago College of Medicine

Research

Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active. Blood Adv. 2021 Oct 06.
View in: PubMed

Racial and Ethnic Enrollment Disparities and Demographic Reporting Requirements in Acute Leukemia Clinical Trials. Blood Adv. 2021 Sep 02.
View in: PubMed

Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)]. Leuk Res. 2021 Jun; 105:106581.
View in: PubMed

A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. Leuk Res. 2021 05; 104:106555.
View in: PubMed

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell. 2021 03 04; 28(3):514-523.e9.
View in: PubMed

Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia? Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):41-50.
View in: PubMed

Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell. 2020 12 14; 38(6):872-890.e6.
View in: PubMed

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020 08 13; 383(7):617-629.
View in: PubMed

P2RY8-CRLF2Fusion-Positive Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Response to Novel Therapy. JCO Precis Oncol. 2020; 4:152-160.
View in: PubMed

Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. Am J Hematol. 2020 03; 95(3):245-250.
View in: PubMed

Prospects for Venetoclax in Myelodysplastic Syndromes. Hematol Oncol Clin North Am. 2020 04; 34(2):441-448.
View in: PubMed

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133.
View in: PubMed

Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol. 2019 09; 32(9):1373-1385.
View in: PubMed

Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations. Am J Hematol. 2018 11; 93(11):1358-1367.
View in: PubMed

Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget. 2018 Feb 20; 9(14):11665-11676.
View in: PubMed

Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive. Drugs Today (Barc). 2017 Oct; 53(10):531-543.
View in: PubMed

The Development of FLT3 Inhibitors in Acute Myeloid Leukemia. Hematol Oncol Clin North Am. 2017 08; 31(4):663-680.
View in: PubMed

Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells. Oncotarget. 2016 Nov 15; 7(46):74917-74930.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
View in: PubMed

Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species. Clin Cancer Res. 2016 Apr 15; 22(8):1978-88.
View in: PubMed

Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leuk Lymphoma. 2016; 57(3):609-15.
View in: PubMed

Regulation of ribosomal gene expression in cancer. J Cell Physiol. 2015 Jun; 230(6):1181-8.
View in: PubMed

Monosomal karyotype acute myeloid leukemia: tread lightly. Acta Haematol. 2015; 133(4):324-6.
View in: PubMed

Blood consult: monosomal karyotype acute myeloid leukemia. Blood. 2012 Jun 14; 119(24):5659-60.
View in: PubMed

Identification and molecular characterization of a novel 3′ mutation in RUNX1 in a family with familial platelet disorder. Leuk Lymphoma. 2010 Oct; 51(10):1931-5.
View in: PubMed

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. Onco Targets Ther. 2010 Jun 24; 3:1-13.
View in: PubMed

Morphogenesis signaling components influence cell cycle regulation by cyclin dependent kinase. Cell Div. 2009 Jul 01; 4:12.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Top